BS-001 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase II drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OH-2 is under development for the treatment of head and neck cancer, liver cancer, hepatocellular carcinoma, lung cancer, lymphoma, non muscle invasive bladder cancer, advanced bladder carcinoma, breast cancer, gastrointestinal cancer, soft tissue sarcoma, metastatic colorectal cancer, esophageal cancer, muscle invasive bladder cancer, recurrent central nervous system tumors including but not limited to anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma, glioma, anaplastic ependymoma, medulloblastoma, malignant meningioma and melanoma. The therapeutic candidate is a recombinant oncolytic herpes simplex virus type 2 (oHSV-2). It is administered through intratumoral route.
It was also under development for the treatment of colon cancer, metastatic pancreatic cancer.
Wuhan Binhui Biopharmaceutical overview
Wuhan Binhui Biopharmaceutical (Binhui) is a biotechnology company, that provides innovative products and services in the field of cancer gene and immunotherapy, committing to improving anti-tumor and cancer drugs. Binhui is headquartered in China.
For a complete picture of BS-001’s drug-specific PTSR and LoA scores, buy the report here.